Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1098 of 6351
-
New heart valve trial offers hope for patients with rare congenital defects
Disease control Recruiting nowThis study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmon…
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Immunotherapy boosts chemo in ovarian cancer fight
Disease control CompletedThis phase II trial studies how well pembrolizumab works when given in combination with carboplatin and paclitaxel in treating patients with stage III-IV ovarian, primary peritoneal, or fallopian tube cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may he…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Smart breathing machines at home: a new way to predict COPD crises?
Disease control CompletedThe prevalence of chronic respiratory disease, including chronic obstructive pulmonary disease (COPD), is increasing in industrialized countries. Over the next decade deaths from COPD are projected to increase by more than 30% and COPD will become the third leading cause of death…
Sponsor: ResMed • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Brain training: behavioral therapy may rewire social circuits in autistic toddlers
Disease control Stopped earlyThe aim of the study is to determine whether a targeted behavioral intervention can lead to both changes in early communication skills and in neural responses in toddlers and preschoolers with autism.
Sponsor: Boston University Charles River Campus • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New immunotherapy cocktail aims to beat melanoma relapse
Disease control OngoingEffective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective. The combination of ipilimumab and nivolumab is the most active regimen in …
Phase 2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
When is the best time for ovarian cancer surgery?
Disease control OngoingThis study consists of three parts, whereas Part 1 and Part 2 are performed in Germany only, and Part 3 is a multinational trial. All patients with suspicion of advanced ovarian cancer are detected in the participating study centers in a pre-screening. The study centers will reg…
Sponsor: AGO Study Group • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New IV drug shows promise for postpartum depression
Symptom relief CompletedThe purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo injection as assessed by the change from baseline in H…
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 17:15 UTC
-
New combo tackles relapsed leukemia after stem cell transplant
Disease control CompletedThis phase IIa trial studies how well guadecitabine works in treating patients with acute myelogenous leukemia and myelodysplastic syndrome that has returned after a period of improvement after allogeneic stem cell transplant. Guadecitabine may stop the growth of cancer cells by …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control OngoingThis research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill shows promise against lung cancer in early trial
Disease control OngoingThis study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the bes…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a common diabetes drug stop oral cancer before it starts?
Prevention OngoingThis phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacter…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy targets genetic weakness in Hard-to-Treat leukemia
Disease control OngoingThe purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitid…
Phase 1/2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a virtual classroom train young brains to tune out distractions?
Symptom relief Recruiting nowProblems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high schoo…
Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Engineered t cells take aim at Hard-to-Treat breast cancer
Disease control OngoingThe purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Smarter radiation dosing aims to cut side effects for head and neck cancer patients
Disease control CompletedThe objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective radiation dose and introduction of an intermediate dose-level in the treatment of head and neck cancer will results in less radiation sequelae and improved quality of life after treatment wh…
Phase 3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for glioblastoma: drug infused directly into brain shows promise
Disease control Recruiting nowPrimary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cance…
Phase 1/2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can rethinking thoughts beat standard OCD therapy?
Disease control CompletedCognitive behavior therapy is the most effective treatment of obsessive-compulsive disorder. However, the majority of treated patients remain symptomatic. The metacognitive therapy by Wells (1997) could achieve substantial gains in first pilot studies. The purpose of this study i…
Sponsor: University of Leipzig • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could adding temsirolimus boost chemo for childhood muscle cancer?
Disease control OngoingThis randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can bionic limbs feel real? a trial tests touch feedback for amputees
Symptom relief By invitation onlyTo assess the functional characteristics and utility of upper and lower limb prosthetic devices (advanced bionic and current clinical standard-of-care) that incorporate physiologically relevant touch and/or movement feedback.
Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC